SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

December 01, 2011 09:00 ET

Therapeutic Solutions International Announces Dr. Reid Jilek as Senior Advisor of Worldwide Marketing

OCEANSIDE, CA--(Marketwire - Dec 1, 2011) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) (PINKSHEETS: TSOI), the only manufacturer of the chairside NTI Tension Suppression System ("NTI-tss") that has helped countless patients prevent debilitating migraine and tension headache pain, announced today that the company retained Reid Jilek, Ph.D. as Senior Advisor responsible for directing the Company's worldwide market development.

Dr. Jilek holds a Ph.D. in Pathology, a M.S. in Biomedical Engineering, a M.S. in Physiology, a M.S. in Zoology, a B.S. in Microbiology and a B.S. in Electrical Engineering. In addition, Dr. Jilek served as a post-doctoral Presidential Fellow with the University of Virginia Medical School, and also received postdoctoral training in the National Library of Medicine and the National Institute of Health. Dr. Jilek has published over 40 papers in national and international peer-reviewed scientific journals and after completing his National Library of Medicine Post-Doctoral training, he developed computer and mathematical models for malaria. Afterwards, Dr. Jilek decided to utilize his medical and scientific acumen in a business development capacity and since 1990 has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies within the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Russia, Israel and Germany. He has also served as the CEO of three companies.

Dr. Jilek is a founding member of the Frederick Research Center, a research institute whose goals include promoting and conducting scientific research in basic, theoretical and applied nature, coordinating and participating in research projects, and collaborating with other national and international research centers and universities for promoting research, as well as the Asia Pacific Alliance Company, an international non-profit organization focused on reproductive health.

Dr. Jilek has developed vast professional contacts worldwide within the healthcare industry and investment world including key figures with the following fields: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.

"Dr. Reid Jilek will be working to develop markets in South America, Mexico, the Pacific Rim, and other countries we have not previously penetrated," said Tim Dixon, Chairman and President of Therapeutic Solutions International. "Dr. Jilek with his vast worldwide business connections and broad experience working in the healthcare industry coupled with his scientific, engineering, and business expertise will assist TSI towards executing its worldwide product development plans."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. is a company that has developed, is producing and currently marketing the FDA approved NTI Tension Suppression System for the prevention of medically diagnosed migraine pain. The NTI dental device is the most cost effective, non-drug method of migraine prevention on the market today. TSI currently has strong International Patent Protection in those countries we are marketing our products into. TSI has several important websites to disseminate information and market their products. Our patient education site located at, and our corporate website for TSI is

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information

  • For more information please contact:

    Jens Dalsgaard
    Constellation Asset Advisors, Inc
    (415) 524-8500